Antibody-Based Therapies for Neurodegeneration

Antibody-Based Therapies for Neurodegeneration

Introduction

Antibody Based Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox">
| Property | Value |
|----------|-------|
| Category | Immunotherapy |
| Target | Pathological proteins, immune modulators |
| Conditions | Alzheimer's, Parkinson's, ALS, Huntington's |
| Stage | Pre-clinical to FDA approved |
| Mechanism | Passive immunization, active immunization |
</div>

Overview

Antibody-Based Therapies for Neurodegeneration

Introduction

Antibody Based Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox">
| Property | Value |
|----------|-------|
| Category | Immunotherapy |
| Target | Pathological proteins, immune modulators |
| Conditions | Alzheimer's, Parkinson's, ALS, Huntington's |
| Stage | Pre-clinical to FDA approved |
| Mechanism | Passive immunization, active immunization |
</div>

Overview

Antibody-based therapies for neurodegenerative diseases represent one of the most active areas of drug development, with multiple FDA approvals in Alzheimer's disease and numerous candidates in clinical trials for Parkinson's, ALS, and other conditions. These therapies employ monoclonal antibodies to target pathological proteins, modulate neuroinflammation, or deliver therapeutic payloads to the brain.

Types of Antibody Therapies

1. Anti-Amyloid Antibodies

The most advanced area of antibody therapy, targeting [amyloid-beta](/proteins/amyloid-beta) in Alzheimer's disease:

| Antibody | Target | Company | Status | Mechanism |
|----------|--------|---------|--------|-----------|
| [Lecanemab](/entities/lecanemab) | [Aβ](/proteins/amyloid-beta) protofibrils | Eisai/Biogen | FDA Approved (2023) | Clears soluble Aβ |
| [Donanemab](/entities/donanemab) | N-terminal Aβ | Eli Lilly | FDA Approved (2024) | Plaque reduction |
| Aducanumab | Aβ plaques | Biogen | FDA Approved (2021) | Amyloid removal |
| Gantenerumab | Aβ plaques | Roche | Withdrawn | Plaque clearance |
| Crenezumab | Oligomeric Aβ | Roche | Discontinued | Oligomer neutralization |
| Solanezumab | Mid-domain Aβ | Eli Lilly | Discontinued | Monomer clearance |

2. Anti-Tau Antibodies

Targeting [tau](/proteins/tau) pathology, often combined with anti-amyloid approaches:

| Antibody | Target | Company | Status | Notes |
|----------|--------|---------|--------|-------|
| Semorinemab | [Tau](/proteins/tau) oligomers | Genentech | Phase II | Motor tau reduction |
| Tilavonemab | Tau | AbbVie | Phase II | N-terminal tau |
| Bepranemab | Tau | UCB | Phase II | Mid-region tau |
| JNJ-63733657 | Tau | Janssen | Phase I | Phospho-tau specific |

3. Anti-Synuclein Antibodies

Targeting [α-synuclein](/proteins/alpha-synuclein) for Parkinson's and related disorders:

| Antibody | Target | Company | Status | Notes |
|----------|--------|---------|--------|-------|
| Prasinezumab | α-Syn | Roche | Phase II | Reduced progression |
| Cinpanemab | α-Syn | Biogen | Phase II | Discontinued |
| ABBV-0805 | α-Syn | AbbVie | Phase I | α-syn targeting |

4. Anti-Huntingtin Antibodies

| Antibody | Target | Company | Status | Notes |
|----------|--------|---------|--------|-------|
| Tominersen | [HTT](/proteins/htt-protein) mRNA | Roche | Discontinued | ASO, not antibody |

5. Neuroinflammation Modulators

Targeting microglial activation and inflammatory pathways:

| Antibody | Target | Company | Status | Notes |
|----------|--------|---------|--------|-------|
| AL003 | [TREM2](/proteins/trem2-protein) | Alector | Phase II | [Microglia](/entities/microglia) activation |
| AL002 | [TREM2](/genes/trem2) | Alector/AbbVie | Phase II | TREM2 agonism |
| Semorinemab | Tau | See above | Phase II | - |

6. Neurotrophic Factor Antibodies

| Antibody | Target | Company | Status | Notes |
|----------|--------|---------|--------|-------|
| Anti-BDNF | BDNF | Various | Pre-clinical | Neutralizes inhibitory BDNF |

Mechanism of Action

Passive Immunization

• Direct clearance: Antibodies bind to target proteins, promoting Fc-mediated phagocytosis
• Oligomer neutralization: Antibodies prevent formation of toxic oligomers
• Plaque targeting: Antibodies cross the [BBB](/entities/blood-brain-barrier) or engage peripheral sink
• Effector function: FcγR engagement activates [microglia](/cell-types/microglia-neuroinflammation)

Active Immunization

• Vaccines: Stimulate endogenous antibody production
• Aβ vaccines: ACC-001, CAD106, ABvac40 (various stages)

Delivery Challenges

Blood-Brain Barrier Penetration

• Only ~0.1-0.5% of circulating antibody enters the brain
• Strategies to improve:
• Receptor-mediated transcytosis (transferrin receptor)
• Bispecific antibodies
• Intrathecal delivery
• Focused ultrasound opening

Peripheral Sink Effects

• Antibody binding in periphery can reduce CNS target
• "Peripheral sink hypothesis" - antibodies act as Aβ sink in blood

Adverse Effects

Amyloid-Related Imaging Abnormalities (ARIA)

• ARIA-E: Cerebral edema, microhemorrhages
• ARIA-H: Cerebral microhemorrhages, hemosiderosis
• Risk factors: ApoE4 homozygosity, high amyloid burden

Other Considerations

• Infusion reactions
• Immunogenicity (anti-drug antibodies)
• Cost and access issues

Future Directions

See Also

• [Anti-Tau Immunotherapies](/therapeutics/anti-tau-immunotherapies)
• [Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)
• [TREM2 Agonist Therapies](/therapeutics/trem2-agonists)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [Antibody Therapy Research - Nature Reviews Drug Discovery](https://www.nature.com/nrd/)
• [Alzheimer's Immunotherapy Research](https://www.sciencedirect.com/)
• [ClinicalTrials.gov - Antibody Therapy](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=antibody)
• [Alzheimer's Association](https://www.alz.org/)
• [FDA - Alzheimer's Disease Vaccines](https://www.fda.gov/)

Background

The study of Antibody Based Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and progress. Alzheimers Dement. 2024;20(1):285-301.

^[2] Sims JR, Zimmer JA, Evans CD, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.

^[3] Swarup V, Dzahini O, Huang Y, et al. Anti-tau antibody therapy for Alzheimer's disease: progress and challenges. Mol Psychiatry. 2023;28(12):5044-5058.

^[4] Pagano M, Taylor KI, Enzinger C, et of prasinezumab in Parkinson's disease. N Engl J Med. 2024;390(9):785-794.

^[5] Masliah E, Rockenstein E, Veinbergs I, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. Proc Natl Acad Sci. 2001;98(24):13681-13686.

^[6] Cumulative summary of anti-amyloid antibodies in clinical trials for Alzheimer's disease. Nat Rev Drug Discov. 2024;23(3):181-200.

^[7] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2024;404(10452):932-946.

^[8] Hampel H, Hardy J, Blennow K, et al. The amyloid-beta cascade hypothesis: ten years later. Alzheimers Dement. 2024;20(1):e2023065967.

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;